GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 143
- Registration Number
- NCT05101096
- Locations
- 🇯🇵
Kagawa University Hospital, Kagawa, Japan
🇯🇵Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Akita University Hospital, Akita, Japan
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 603
- Registration Number
- NCT05089734
- Locations
- 🇺🇸
Maryland Oncology Hematology, P.A., Clinton, Maryland, United States
🇺🇸W.G (Bill) Hefner VAMC, Salisbury, North Carolina, United States
🇺🇸Florida Cancer Specialists, West Palm Beach, Florida, United States
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 378
- Registration Number
- NCT05079230
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UC Irvine Health- Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸The University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 142
- Registration Number
- NCT05052996
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc, Los Angeles, California, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
🇺🇸Emory University Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 195
- Registration Number
- NCT05006794
- Locations
- 🇺🇸
Novant Health Cancer Institute - Elizabeth (Breast Cancer), Charlotte, North Carolina, United States
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah Medical Center- Ein Kerem, Jerusalem, Israel
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 376
- Registration Number
- NCT05007782
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Smilow Cancer Center, New Haven, Connecticut, United States
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 5368
- Registration Number
- NCT04994509
- Locations
- 🇿🇦
Emavundleni Research Centre, Cape Town, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
🇿🇦Synergy Biomed Research Institute (SBRI), East London, South Africa
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 457
- Registration Number
- NCT04971785
- Locations
- 🇺🇸
Charter Research, Winter Park, Florida, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Rush University Medical Group - Department of Hepatology, Chicago, Illinois, United States
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT04958785
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇺🇸Charleston Oncology, Charleston, South Carolina, United States
🇦🇺Peninsula Health, Frankston, Victoria, Australia
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
- Conditions
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT04950764
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸University of California Davis, Sacramento, California, United States
🇺🇸University of Colorado Anschutz, Aurora, Colorado, United States